In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 6, 2003, Pages 915-919

  Veloira, Wilfredo G ^a   Domenico, Philip ^a   LiPuma, John J ^b   Davis J M , Jonathan M ^a   Gurzenda, Ellen ^a   Kazzaz, Jeffrey A ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aminoglycosides; Antibiotics; Bacterial polysaccharide; Biofilms; Cystic fibrosis

Indexed keywords

BISMUTH 1,2 ETHANEDITHIOL; BISMUTH 2,3 DIMERCAPTOTOLUENE; BISMUTH 3 MERCAPTO 2 BUTANOL; BISMUTH 4 CHLOROTHIOPHENOL; BISMUTH DERIVATIVE; BISMUTH PYRITHIONE; BISMUTH SALT; DIMERCAPROL; DITHIOL DERIVATIVE; PYRITHIONE; THIOL DERIVATIVE; THIOPHENOL DERIVATIVE; TOBRAMYCIN; TOLUENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA MULTIVORANS; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG CONCENTRATION; DRUG POTENCY; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION;

ANTI-BACTERIAL AGENTS; BISMUTH; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; SULFHYDRYL COMPOUNDS; TOBRAMYCIN;

EID: 0348149157     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg471     Document Type: Article

References (41)

1. Burkholder, W. H. (1950). Sour skin, a bacterial rot of onion bulbs. Phytopathology 50, 115-17.
2. Isles, A., Maclusky, I. & Corey, M. (1984). Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. Journal of Pediatrics 104, 206-10.
3. Speert, D. P., Bond, M., Woodman, R. C. et al. (1994). Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. Journal of Infectious Diseases 170, 1524-31.
4. Cystic Fibrosis Foundation. Patient Registry Annual Report. Bethesda, MD, USA, September 1999.
5. Brown, P., Butler, S. & Nelson, J. (1993). Pseudomonas cepacia in adult cystic fibrosis: accelerated decline in lung function and increased mortality. Thorax 48, 425-9.
6. Lewin, L., Byard, P. & Davis, P. (1990). Effect of Pseudomonas cepacia colonization on survival and pulmonary function in cystic fibrosis patients. Journal of Clinical Epidemiology 43, 125-30.
7. Snell, G. I., de Hoyos, A., Krajden, M. et al. (1993). Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 103, 466-71.
8. Chapparo, C., Maurere, J., Gutierrez, C. A. et al. (2001). Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. American Journal of Respiratory and Critical Care Medicine 163, 43-8.
9. Coenye, T., Vandamme, P., Govan, J. R. W. et al. (2001). Taxonomy and identification of the Burkholderia cepacia complex. Journal of Clinical Microbiology 39, 3427-36.
10. Vandamme, P., Henry, D., Coenye, T. et al. (2002). Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunology and Medical Microbiology 33, 143-9.
11. Vandamme, P., Holmes, B., Coenye, T. et al. (2003). Burkholderia cenocepacia sp. nov., a new twist to an old story. Research in Microbiology 154, 91-6.
12. Speert, D. P., Henry, D., Vandamme, P. et al. (2002). Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerging Infectious Diseases 8, 181-7.
13. Agodi, A., Mahenthiralingam, E., Barchitta, M. et al. (2001) Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology and genomovar status. Journal of Clinical Microbiology 39, 2891-6.
14. Parke, J. L. & Gurian-Sherman, D. (2001). Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains. Annual Reviews of Phytopathology 39, 225-58.
15. LiPuma, J. J., Spilker, T., Gill, L. H. et al. (2001). Disproportionate distribution of Burkholderia cepacia complex species and transmissibility in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 164, 92-6.
16. Regelmann, W., Elliot, G., Warwick, W. et al. (1990). Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease 141, 914-21.
17. Smith, A., Doershuck, C., Goldman, D. et al. (1999). Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 134, 413-21.
18. Gold, R. E., Jin, E., Levison, H. et al. (1983). Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. Journal of Antimicrobial Chemotherapy 12, Suppl. A, 331-6.
19. Gold, R. A., Overmeyer, A., Knie, B. et al. (1985). Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric Infectious Disease 4, 172-7.
20. Fass, R. J. & Barnishan, J. (1980). In vitro susceptibilities of non-fermentative Gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Reviews of Infectious Diseases 2, 841-53.
21. Aaron, S. D., Ferris, W., Henry, D. A. et al. (2000). Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine 161, 1206-12.
22. Domenico, P., Salo, R. J., Novick, S. G. et al. (1997). Enhancement of bismuth antibacterial activity with lipophilic thiol chelators. Antimicrobial Agents and Chemotherapy 41, 1697-1703.
23. Domenico, P., Tomas, J. M., Merino, S. et al. (1999). Surface antigen exposure by bismuth dimercaprol suppression of Klebsiella pneumoniae capsular polysaccharide. Infection and Immunity 67, 664-9.
24. Domenico, P., Baldassari, L., Schoch, P. E. et al. (2001). Activities of bismuth thiols against staphylococci and staphylococcal biofilms. Antimicrobial Agents and Chemotherapy 45, 1417-21.
25. Wu, C. L., Domenico, P., Hassett, D. J. et al. (2002). Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. American Journal of Respiratory Cell and Molecular Biology 26, 731-8.
26. Dill, K. & McGown, E. L. (1994). The biochemistry of arsenic, bismuth and antimony. In The Chemistry of Organic Arsenic, Antimony and Bismuth Compounds (Patai, S., Ed.), pp. 695-713. John Wiley & Sons, New York, NY, USA.
27. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A2 and Informational Supplement M100-S10. NCCLS, Wayne, PA, USA.
28. Eliopoulos, G. M. & Moellering, R. C. (1996). Antimicrobial combinations. In Antibiotics in Laboratory Medicine (Lorian, V., Ed.), pp. 330-96. Williams and Wilkins, Baltimore, MD, USA.
29. Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy 52, 1.
30. Amsterdam, D. (1996). Susceptibility testing of antimicrobials in liquid media. In Antibiotics in Laboratory Medicine, 4th edn (Lorian, V., Ed.), pp. 52-111. Williams and Wilkins, Baltimore, MD, USA.
31. Moore, R. A. & Hancock, R. E. W. (1986). Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrobial Agents and Chemotherapy 30, 923-6.
32. Moore, R. A., Bates, N. C. & Hancock, R. E. W. (1986). Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied using dansyl-polymyxin. Antimicrobial Agents and Chemotherapy 29, 496-500.
33. Hancock, R. E. W. (1984). Alterations in outer membrane permeability. Annual Review of Microbiology 38, 237-64.
34. Nzula, S., Vandamme, P. & Govan, J. R. (2002). Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. Journal of Antimicrobial Chemotherapy 50, 265-9.
35. Beil, W., Birkholz, C., Wagner, S. et al. (1995). Bismuth subcitrate and omeprazole inhibit Helicobacter pylori F1-ATPase. Pharmacology 50, 333-7.
36. Sox, T. E. & Olson, C. A. (1989). Binding and killing of bacteria by bismuth subsalicylate. Antimicrobial Agents and Chemotherapy 33, 2075-82.
37. Domenico, P., Kazzaz, J. A. & Davis, J. M. (2003). Combating antibiotic resistance with bismuth-thiols. Research Advances in Antimicrobial Agents & Chemotherapy 3, 79-85.
38. Domenico, P., Landolphi, D. R. & Cunha, B. A. (1991). Reduction of capsular polysaccharide and potentiation of aminoglycoside inhibition in Gram-negative bacteria by bismuth subsalicylate. Journal of Antimicrobial Chemotherapy 28, 801-10.
39. Domenico, P., Parikh, D. & Cunha, B. A. (1994) Bismuth modulation of antibiotic activity against gastrointestinal bacterial pathogens. Medical Microbiology Letters 3, 114-19.
40. Wichelhaus, T. A., Boddinghaus, B., Besier, S. et al. (2002). Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 46, 3381-5.
41. Geller, D. E., Pitlick, W. H., Nardella, P. A. et al. (2002). Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122, 219-26.